Advertisement

Citations to this article

Abstract

Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.

Authors

Sizhi Paul Gao ... Bayard Clarkson, Jacqueline F. Bromberg

×

Total citations by year

Year: 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 1 41 32 32 29 26 31 15 1 208
Citation information

Citations to this article in year 2012 (32)

Title and authors Publication Year
Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression Profiling
MB Freidin, N Bhudia, E Lim, AG Nicholson, WO Cookson, MF Moffatt
Journal of Molecular Diagnostics 2012
The role of pseudokinases in cancer
H Zhang, A Photiou, G Arnhild, J Stebbing, G Giamas
Cellular Signalling 2012
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
ZC Ding, G Zhou
Clinical and Developmental Immunology 2012
Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment
HJ Hugo, S Lebret, E Tomaskovic-Crook, N Ahmed, T Blick, DF Newgreen, EW Thompson, ML Ackland
Cancer Microenvironment 2012
Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling
X Jin, SH Kim, HM Jeon, S Beck, YW Sohn, J Yin, JK Kim, YC Lim, JH Lee, SH Kim, SH Kang, X Pian, MS Song, JB Park, YS Chae, YG Chung, SH Lee, YJ Choi, DH Nam, YK Choi, H Kim
Brain 2012
p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway
P Ozenne, D Dayde, E Brambilla, B Eymin, S Gazzeri
Oncogene 2012
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
D Harada, N Takigawa, N Ochi, T Ninomiya, M Yasugi, T Kubo, H Takeda, E Ichihara, K Ohashi, S Takata, M Tanimoto, K Kiura
Cancer Science 2012
Curcumin Blocks Small Cell Lung Cancer Cells Migration, Invasion, Angiogenesis, Cell Cycle and Neoplasia through Janus Kinase-STAT3 Signalling Pathway
CL Yang, YY Liu, YG Ma, YX Xue, DG Liu, Y Ren, XB Liu, Y Li, Z Li
PloS one 2012
Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas
T Plönes, A Krohn, M Burger, H Veelken, B Passlick, J Müller-Quernheim, G Zissel
PloS one 2012
Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-α
K Kanda, H Komekado, T Sawabu, S Ishizu, Y Nakanishi, M Nakatsuji, R Akitake-Kawano, M Ohno, Y Hiraoka, M Kawada, K Kawada, Y Sakai, K Matsumoto, M Kunichika, T Kimura, H Seno, E Nishi, T Chiba
EMBO Molecular Medicine 2012
ER stress-induced inflammation: does it aid or impede disease progression?
AD Garg, A Kaczmarek, O Krysko, P Vandenabeele, DV Krysko, P Agostinis
Trends in Molecular Medicine 2012
Involvement of STAT3, NF-κB and associated downstream molecules before and after the onset of urethane induced lung tumors in mouse
M Pandey, KP Gupta
Environmental Toxicology and Pharmacology 2012
Interleukin-6 signaling pathway in targeted therapy for cancer
Y Guo, F Xu, TJ Lu, Z Duan, Z Zhang
Cancer Treatment Reviews 2012
DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors
UJ Yun, SE Park, YS Jo, J Kim, DY Shin
Cancer Letters 2012
Acetylation modulates the STAT signaling code
M Wieczorek, T Ginter, P Brand, T Heinzel, OH Krämer
Cytokine & Growth Factor Reviews 2012
Stat3: Linking inflammation to (gastrointestinal) tumourigenesis
M Ernst, TL Putoczki
Clinical and Experimental Pharmacology and Physiology 2012
Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer
N Singh, S Hussain, M Bharadwaj, N Kakkar, SK Singh, RC Sobti
Journal of Receptors and Signal Transduction 2012
STAT3 as a therapeutic target for Epstein-Barr virus (EBV) – associated nasopharyngeal carcinoma
Y Ho, SW Tsao, M Zeng, VW Lui
Cancer Letters 2012
Radioimmunoimaging with Mixed Monoclonal Antibodies of Nude Mice Bearing Human Lung Adenocarcinoma Xenografts
D Duan, SL Li, YQ Zhu, T Zhang, CM Lei, XH Cheng
Asian Pacific Journal of Cancer Prevention 2012
STAT3 negatively regulates thyroid tumorigenesis
JP Couto, L Daly, A Almeida, JA Knauf, JA Fagin, M Sobrinho-Simões, J Lima, V Máximo, P Soares, D Lyden, JF Bromberg
Proceedings of the National Academy of Sciences 2012
Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo
S Vicent, LC Sayles, D Vaka, P Khatri, O Gevaert, R Chen, Y Zheng, AK Gillespie, N Clarke, Y Xu, J Shrager, CD Hoang, S Plevritis, AJ Butte, EA Sweet-Cordero
Cancer research 2012
Targeting the interleukin-6/Jak/stat pathway in human malignancies
P Sansone, J Bromberg
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012
Determinants of the extent and duration of STAT3 signaling
B Groner
JAK-STAT 2012
Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer
MG Alexandrow, LJ Song, S Altiok, J Gray, EB Haura, NB Kumar
European Journal of Cancer Prevention 2012
Pyruvate Kinase M2 Regulates Gene Transcription by Acting as A Protein Kinase
X Gao, H Wang, JY Jenny, X Liu, ZR Liu
Molecular Cell 2012

Advertisement
Advertisement